| 标题： | 中国双相障碍防治指南（第三版） |
| title： | Chinese Guidelines for the Prevention and Management of Bipolar Disorders (Third version) |
| 版本： | 更新版 |
| version： | Updated |
| 分类： | 标准指南 |
| classification： | Standard guideline |
| 领域： | 综合 |
| field： | Comprehensive guideline |
| 国家和地区： | 中国 |
| Country and region： | China |
| 指南使用者： | 精神科医师，全科医师，临床药师，护士，研究者，医学院教师，心理咨询师，康复治疗师 |
| Guide users： | Psychiatrists, General physicians, Clinical pharmacists, Nurses, Researchers, Medical school teachers, Psychological consultants, Rehabilitation physiatrists |
| 证据分级方法： | Level 1: At least two replicated double-blind (DB), randomized controlled trial (RCT) that includes a placebo or active control comparison (n ≥ 30 in each active treatment arm), or meta-analysis with narrow confidence interval Level 2: At least one double-blind (DB), randomized controlled trial (RCT) that includes a placebo or active control comparison (n ≥ 30 in each active treatment arm), or meta-analysis with wide confidence interval Level 3: At least one double-blind (DB), randomized controlled trial (RCT) that includes a placebo or active control comparison (n = 10-29 in each active treatment arm), or high-quality retrospective study Level 4: Open-label trial, prospective non-randomized uncontrolled trial, case report, expert opinion/consensus |
| Evidence grading method： | 1级：至少2项重复的双盲随机对照试验，包括安慰剂或者阳性对照（治疗组例数至少超过30例），或具有窄置信区间的荟萃分析 2级：至少1项双盲随机对照试验，包括安慰剂或者阳性对照（治疗组例数至少超过30例），或具有宽置信区间的荟萃分析 3级：至少1项双盲随机对照试验，包括安慰剂或者阳性对照（治疗组例数在10-29例之间），或高质量的回顾性研究 4级：开放标签试验，前瞻性非随机对照试验，病例报告，专家建议/共识 |
| 制定单位： | 中华医学会精神医学分会 |
| Formulating unit： | Chinese Society of Psychiatry |
| 注册时间： | 2023-05-25 |
| Registration time： | |
| 注册编号： | PREPARE-2023CN360 |
| Registration number： | |
| 指南制订的目的： | 2007年、2015年中华医学会精神医学分会（CSP）分别发布了中国《双相障碍防治指南》第一版、第二版。中国《双相障碍防治指南》（第二版）得到国内同仁、学者积极响应，临床应用广泛，至今已经加印2次。通过在“Bipolar Disorders”杂志的介绍，让全球同行了解了中国双相障碍的诊治策略及其进展。随着精神医学的快速发展，精神医学领域对双相障碍的关注日趋加强、产生新的循证证据日益增多。国际不同国家/地区/学术组织陆续更新/再版了《双相障碍治疗指南》，包括CANMAT/ISBD、BAP、CINP等。国内学界针对双相障碍的研究发展迅速，除研究其机制、评估、诊断、鉴别、治疗方法等方面外，更涉及青少年、共病等特殊人群的探讨。中国近年来拾遗补缺地发表了双相相关《共识》、《建议》、《精准指南》等。随诊临床医学的发展和学科交叉融合，尤其脑机接口技术、人工智能、大数据分析技术的快速发展，给双相障碍的诊断、治疗提供了新的方法与路径。综上，再版《双相障碍防治指南》，为中国精神科临床实践提供更合理、更有效、与时俱进的诊治方案势在必行。 |
| Purpose of the guideline： | The Chinese Society of Psychiatry (CSP) published the first and second versions of the Chinese guidelines for the prevention and management of bipolar disorder in 2007 and 2015, respectively. The second version of the Chinese guidelines for bipolar disorder has received positive responses from domestic psychiatrists and scholars and has been widely used in clinical practice in China. The pragmatic guidelines have been reprinted twice for clinical use. In addition, the introduction of the guidelines has been published in BIPOLAR DISORDERS, which acquaints clinicians and specialists around the world with Chinese practice in bipolar disorder. With the rapid development of psychiatry, more and more attention has been attracted to the bipolar field, and new evidence accumulates rapidly. In the context of evidence-based clinical practice, worldwide countries/regions/societies have been updating the management of patients with bipolar disorder, including CANMAT/ISBD、BAP、CINP, et al. Meanwhile, comprehensive progress in bipolar disorder has been made in China, including pathogenesis, assessment, diagnoses, and treatments. Particular patients with bipolar disorders, like children and adolescents and patients comorbid with other medical conditions, have been widely studied and discussed in China. In recent years, China has published a series of consensus, suggestions, and precise guidelines for bipolar disorder. New approaches to the assessment and management of bipolar disorder constantly emerge based on the advances in clinical medicine and interdisciplinarity, such as brain-computer interface, artificial intelligence， and big data analysis. In summary, it is imperative to republish the Chinese guidelines for the prevention and management of bipolar disorder to provide more appropriate, effective, and up-to-date diagnosis and treatment strategies for Chinese psychiatric practice. |
最新注册
